BRAF inhibitor encorafenib
E1394947
UNEXPLORED
BRAF inhibitor encorafenib is a targeted cancer therapy used primarily to treat tumors harboring specific BRAF mutations, such as certain forms of melanoma and colorectal cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| BRAF inhibitor encorafenib canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T19772732 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: BRAF inhibitor encorafenib Context triple: [Array BioPharma, hasTherapy, BRAF inhibitor encorafenib]
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
nivolumab
Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
-
C.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
D.
LOXO-305
LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
-
E.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: BRAF inhibitor encorafenib Target entity description: BRAF inhibitor encorafenib is a targeted cancer therapy used primarily to treat tumors harboring specific BRAF mutations, such as certain forms of melanoma and colorectal cancer.
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
nivolumab
Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
-
C.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
-
D.
LOXO-305
LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
-
E.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.